| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophils | 18 | 2024 | 177 | 5.480 |
Why?
|
| Myocardial Infarction | 8 | 2022 | 342 | 4.310 |
Why?
|
| Calgranulin A | 9 | 2021 | 10 | 3.540 |
Why?
|
| Atherosclerosis | 12 | 2022 | 91 | 3.450 |
Why?
|
| Cardiovascular Diseases | 9 | 2022 | 346 | 3.400 |
Why?
|
| Calgranulin B | 7 | 2021 | 17 | 2.640 |
Why?
|
| Diabetes Mellitus, Experimental | 14 | 2021 | 94 | 2.540 |
Why?
|
| Inflammation | 8 | 2024 | 594 | 1.910 |
Why?
|
| Inflammasomes | 3 | 2022 | 19 | 1.710 |
Why?
|
| Myelopoiesis | 8 | 2020 | 10 | 1.550 |
Why?
|
| Granulocytes | 2 | 2021 | 6 | 1.490 |
Why?
|
| Monocytes | 9 | 2020 | 131 | 1.390 |
Why?
|
| Animals | 44 | 2024 | 9918 | 1.320 |
Why?
|
| Hyperglycemia | 3 | 2021 | 77 | 1.310 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 4 | 2022 | 15 | 1.160 |
Why?
|
| Diet, High-Fat | 4 | 2024 | 130 | 1.060 |
Why?
|
| Liver | 5 | 2019 | 414 | 0.950 |
Why?
|
| Cardiovascular System | 2 | 2020 | 39 | 0.900 |
Why?
|
| Extracellular Traps | 2 | 2020 | 9 | 0.900 |
Why?
|
| Insulin Resistance | 6 | 2023 | 165 | 0.840 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2009 | 38 | 0.810 |
Why?
|
| Thrombosis | 2 | 2014 | 147 | 0.800 |
Why?
|
| Receptors, LDL | 4 | 2021 | 28 | 0.790 |
Why?
|
| Hypertension | 4 | 2018 | 304 | 0.780 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 44 | 0.760 |
Why?
|
| Diabetes Complications | 1 | 2021 | 65 | 0.750 |
Why?
|
| Cigarette Smoking | 1 | 2022 | 75 | 0.750 |
Why?
|
| Humans | 29 | 2024 | 26755 | 0.740 |
Why?
|
| Leukopoiesis | 1 | 2020 | 2 | 0.730 |
Why?
|
| Male | 28 | 2024 | 12824 | 0.730 |
Why?
|
| Macrophages | 5 | 2020 | 272 | 0.720 |
Why?
|
| S100 Proteins | 1 | 2020 | 5 | 0.710 |
Why?
|
| Mice | 17 | 2024 | 4389 | 0.700 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 152 | 0.700 |
Why?
|
| Syndecan-4 | 1 | 2019 | 4 | 0.690 |
Why?
|
| Vasoconstriction | 3 | 2010 | 41 | 0.690 |
Why?
|
| Lipoproteins | 2 | 2018 | 95 | 0.690 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 247 | 0.680 |
Why?
|
| Disease Models, Animal | 11 | 2020 | 1391 | 0.680 |
Why?
|
| ErbB Receptors | 2 | 2010 | 96 | 0.660 |
Why?
|
| Gene Deletion | 1 | 2019 | 115 | 0.660 |
Why?
|
| Mice, Knockout | 11 | 2021 | 779 | 0.640 |
Why?
|
| Oxidative Stress | 4 | 2021 | 618 | 0.640 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2018 | 120 | 0.640 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2022 | 192 | 0.630 |
Why?
|
| Mice, Inbred C57BL | 12 | 2024 | 1468 | 0.630 |
Why?
|
| Hepatitis | 1 | 2018 | 7 | 0.620 |
Why?
|
| Thrombopoiesis | 1 | 2018 | 6 | 0.620 |
Why?
|
| Blood Pressure | 5 | 2009 | 351 | 0.620 |
Why?
|
| Phlorhizin | 1 | 2018 | 1 | 0.620 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 6 | 0.620 |
Why?
|
| Glucosides | 1 | 2018 | 8 | 0.620 |
Why?
|
| Blood Glucose | 6 | 2020 | 300 | 0.610 |
Why?
|
| Rats | 14 | 2012 | 1535 | 0.610 |
Why?
|
| Rats, Wistar | 11 | 2012 | 145 | 0.600 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 36 | 0.600 |
Why?
|
| Body Composition | 1 | 2019 | 260 | 0.590 |
Why?
|
| Adipose Tissue | 2 | 2019 | 179 | 0.570 |
Why?
|
| Biomarkers | 7 | 2020 | 729 | 0.560 |
Why?
|
| Signal Transduction | 8 | 2021 | 1332 | 0.540 |
Why?
|
| Diabetic Angiopathies | 2 | 2021 | 47 | 0.510 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2010 | 77 | 0.500 |
Why?
|
| Obesity | 3 | 2024 | 645 | 0.490 |
Why?
|
| Interleukin-1beta | 3 | 2022 | 40 | 0.490 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2012 | 14 | 0.490 |
Why?
|
| Mesenteric Arteries | 2 | 2012 | 8 | 0.490 |
Why?
|
| Acetylcysteine | 4 | 2006 | 24 | 0.470 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2014 | 5 | 0.460 |
Why?
|
| Cholesterol | 4 | 2019 | 181 | 0.450 |
Why?
|
| Bone Marrow | 4 | 2022 | 76 | 0.450 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2020 | 109 | 0.440 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 73 | 0.440 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 118 | 0.430 |
Why?
|
| Bone Density | 2 | 2021 | 99 | 0.420 |
Why?
|
| Heart Rate | 4 | 2009 | 374 | 0.420 |
Why?
|
| Blood Platelets | 4 | 2021 | 203 | 0.420 |
Why?
|
| Triglycerides | 4 | 2019 | 116 | 0.410 |
Why?
|
| Endothelium, Vascular | 4 | 2012 | 305 | 0.410 |
Why?
|
| Doxycycline | 1 | 2012 | 19 | 0.400 |
Why?
|
| Protein Kinase C | 2 | 2009 | 72 | 0.400 |
Why?
|
| Myocardium | 5 | 2019 | 171 | 0.380 |
Why?
|
| Streptozocin | 5 | 2018 | 11 | 0.380 |
Why?
|
| Phenylephrine | 2 | 2010 | 13 | 0.370 |
Why?
|
| Hematopoiesis | 3 | 2020 | 24 | 0.360 |
Why?
|
| Myocytes, Cardiac | 3 | 2009 | 59 | 0.360 |
Why?
|
| Glucose | 4 | 2021 | 190 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 120 | 0.360 |
Why?
|
| Cells, Cultured | 7 | 2019 | 967 | 0.360 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2010 | 2 | 0.350 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 3 | 0.350 |
Why?
|
| Bone Marrow Transplantation | 3 | 2019 | 41 | 0.350 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2010 | 9 | 0.350 |
Why?
|
| Cardiac Myosins | 1 | 2010 | 12 | 0.350 |
Why?
|
| Leukocytes | 3 | 2022 | 68 | 0.350 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 132 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2020 | 58 | 0.340 |
Why?
|
| Maleimides | 1 | 2009 | 6 | 0.340 |
Why?
|
| Receptors, Adrenergic | 1 | 2009 | 9 | 0.340 |
Why?
|
| Metalloproteases | 1 | 2009 | 7 | 0.340 |
Why?
|
| Free Radical Scavengers | 2 | 2006 | 23 | 0.340 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2009 | 7 | 0.330 |
Why?
|
| Endothelial Cells | 1 | 2012 | 324 | 0.330 |
Why?
|
| Phenotype | 3 | 2020 | 661 | 0.330 |
Why?
|
| Adenosine Triphosphate | 1 | 2009 | 115 | 0.320 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 129 | 0.320 |
Why?
|
| Indoles | 1 | 2009 | 97 | 0.310 |
Why?
|
| Time Factors | 4 | 2020 | 1564 | 0.280 |
Why?
|
| Nitrates | 2 | 2006 | 45 | 0.280 |
Why?
|
| Withania | 1 | 2006 | 1 | 0.270 |
Why?
|
| Calcification, Physiologic | 1 | 2006 | 4 | 0.270 |
Why?
|
| Ovariectomy | 1 | 2006 | 53 | 0.260 |
Why?
|
| Nitric Oxide Synthase Type III | 4 | 2012 | 54 | 0.260 |
Why?
|
| Fructose | 3 | 2012 | 22 | 0.250 |
Why?
|
| Tungsten Compounds | 1 | 2005 | 1 | 0.250 |
Why?
|
| Female | 8 | 2024 | 14408 | 0.250 |
Why?
|
| Nitric Oxide | 4 | 2012 | 151 | 0.250 |
Why?
|
| Calcium | 1 | 2006 | 231 | 0.250 |
Why?
|
| Reactive Oxygen Species | 2 | 2021 | 277 | 0.250 |
Why?
|
| Osteoporosis | 2 | 2021 | 63 | 0.240 |
Why?
|
| Cardiomyopathies | 1 | 2005 | 32 | 0.240 |
Why?
|
| Vascular Diseases | 1 | 2005 | 67 | 0.240 |
Why?
|
| Intra-Abdominal Fat | 1 | 2024 | 20 | 0.240 |
Why?
|
| Hypoglycemic Agents | 1 | 2005 | 105 | 0.230 |
Why?
|
| Heart Diseases | 2 | 2023 | 68 | 0.230 |
Why?
|
| Pseudomonas Infections | 1 | 2023 | 24 | 0.220 |
Why?
|
| Insulin | 3 | 2014 | 309 | 0.220 |
Why?
|
| Capillary Permeability | 2 | 2021 | 38 | 0.220 |
Why?
|
| Interleukin-1alpha | 1 | 2022 | 7 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2023 | 699 | 0.200 |
Why?
|
| Phagocytosis | 1 | 2022 | 78 | 0.200 |
Why?
|
| Tobacco | 1 | 2022 | 86 | 0.200 |
Why?
|
| Nicotine | 1 | 2022 | 82 | 0.200 |
Why?
|
| Cell Adhesion | 1 | 2022 | 132 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2012 | 40 | 0.190 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2020 | 6 | 0.190 |
Why?
|
| Thrombocytosis | 2 | 2018 | 2 | 0.190 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2020 | 4 | 0.180 |
Why?
|
| Lysine | 3 | 2009 | 69 | 0.180 |
Why?
|
| Cholesterol, Dietary | 2 | 2018 | 6 | 0.180 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2020 | 13 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 54 | 0.180 |
Why?
|
| Cell Death | 1 | 2020 | 110 | 0.180 |
Why?
|
| Diabetic Foot | 1 | 2020 | 16 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2020 | 10 | 0.180 |
Why?
|
| Antioxidants | 3 | 2006 | 222 | 0.180 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 34 | 0.170 |
Why?
|
| Diet, Western | 1 | 2020 | 18 | 0.170 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2019 | 6 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2019 | 6 | 0.170 |
Why?
|
| Matrix Metalloproteinase 7 | 2 | 2010 | 13 | 0.170 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 453 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2019 | 66 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 321 | 0.160 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 207 | 0.160 |
Why?
|
| Adiposity | 1 | 2019 | 87 | 0.160 |
Why?
|
| Blood | 1 | 2019 | 33 | 0.160 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 110 | 0.160 |
Why?
|
| Regenerative Medicine | 1 | 2018 | 17 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 123 | 0.160 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2018 | 32 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 129 | 0.160 |
Why?
|
| Sympathetic Nervous System | 1 | 2018 | 64 | 0.160 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 105 | 0.160 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2020 | 12 | 0.150 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 186 | 0.150 |
Why?
|
| Smoking | 1 | 2022 | 465 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 254 | 0.150 |
Why?
|
| Proteoglycans | 1 | 2018 | 37 | 0.150 |
Why?
|
| Sex Factors | 1 | 2019 | 444 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2018 | 32 | 0.150 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 79 | 0.150 |
Why?
|
| Leukocytosis | 2 | 2018 | 2 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2019 | 282 | 0.150 |
Why?
|
| Methoxamine | 2 | 2009 | 2 | 0.150 |
Why?
|
| Heparin | 1 | 2018 | 110 | 0.150 |
Why?
|
| Tyrosine | 2 | 2009 | 90 | 0.150 |
Why?
|
| Bacteria | 1 | 2019 | 264 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 119 | 0.140 |
Why?
|
| Risk Factors | 2 | 2021 | 2012 | 0.140 |
Why?
|
| Retina | 1 | 2020 | 413 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 537 | 0.130 |
Why?
|
| Lipolysis | 1 | 2014 | 5 | 0.120 |
Why?
|
| Hypertriglyceridemia | 1 | 2014 | 8 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2018 | 845 | 0.120 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 12 | 0.120 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2014 | 12 | 0.120 |
Why?
|
| Pluripotent Stem Cells | 1 | 2014 | 7 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2006 | 503 | 0.110 |
Why?
|
| Body Weight | 3 | 2020 | 245 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2014 | 761 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2014 | 69 | 0.110 |
Why?
|
| Mitochondria | 2 | 2023 | 324 | 0.110 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2013 | 2 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2013 | 3 | 0.110 |
Why?
|
| Glycation End Products, Advanced | 1 | 2013 | 16 | 0.110 |
Why?
|
| Vasculitis | 1 | 2013 | 13 | 0.110 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 35 | 0.110 |
Why?
|
| Cholesterol, HDL | 1 | 2013 | 59 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2013 | 67 | 0.110 |
Why?
|
| Diiodothyronines | 1 | 2012 | 1 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 64 | 0.110 |
Why?
|
| Triiodothyronine | 1 | 2012 | 19 | 0.100 |
Why?
|
| Coronary Disease | 1 | 2013 | 118 | 0.100 |
Why?
|
| Protein Kinase C beta | 2 | 2009 | 4 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2014 | 244 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2013 | 187 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2018 | 2262 | 0.100 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 49 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 3 | 2006 | 34 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2012 | 61 | 0.100 |
Why?
|
| Cytokines | 1 | 2013 | 437 | 0.090 |
Why?
|
| Cattle | 1 | 2012 | 383 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2010 | 6 | 0.090 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 11 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 45 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 44 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 40 | 0.090 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2010 | 38 | 0.090 |
Why?
|
| Mannitol | 1 | 2009 | 2 | 0.080 |
Why?
|
| RNA Interference | 1 | 2010 | 135 | 0.080 |
Why?
|
| Enzyme Induction | 1 | 2009 | 27 | 0.080 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2009 | 3 | 0.080 |
Why?
|
| Nitrites | 2 | 2006 | 29 | 0.080 |
Why?
|
| Transfection | 1 | 2010 | 312 | 0.080 |
Why?
|
| Myocardial Contraction | 2 | 2008 | 60 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2010 | 239 | 0.080 |
Why?
|
| Models, Animal | 1 | 2009 | 128 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2009 | 77 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 142 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2010 | 557 | 0.080 |
Why?
|
| Aorta | 1 | 2009 | 123 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 145 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2008 | 18 | 0.080 |
Why?
|
| Cardiomegaly | 1 | 2006 | 18 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 22 | 0.070 |
Why?
|
| Isoprostanes | 1 | 2006 | 3 | 0.070 |
Why?
|
| ATP Binding Cassette Transporter 1 | 2 | 2018 | 11 | 0.070 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 68 | 0.070 |
Why?
|
| Testosterone | 1 | 2006 | 68 | 0.070 |
Why?
|
| Plant Roots | 1 | 2006 | 46 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2006 | 62 | 0.060 |
Why?
|
| Neurotensin | 1 | 2005 | 4 | 0.060 |
Why?
|
| Amidines | 1 | 2005 | 8 | 0.060 |
Why?
|
| Benzylamines | 1 | 2005 | 19 | 0.060 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2005 | 31 | 0.060 |
Why?
|
| Heart Function Tests | 1 | 2005 | 10 | 0.060 |
Why?
|
| Drinking | 1 | 2005 | 8 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 624 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2005 | 22 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2006 | 90 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2005 | 54 | 0.060 |
Why?
|
| Glucose Tolerance Test | 1 | 2005 | 57 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2023 | 578 | 0.060 |
Why?
|
| Eating | 1 | 2005 | 66 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2005 | 166 | 0.060 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 100 | 0.060 |
Why?
|
| Neutrophil Infiltration | 1 | 2024 | 19 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2024 | 35 | 0.060 |
Why?
|
| Hemodynamics | 1 | 2005 | 220 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2018 | 644 | 0.060 |
Why?
|
| Feces | 1 | 2024 | 107 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2023 | 39 | 0.050 |
Why?
|
| Microbiota | 1 | 2024 | 79 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2023 | 62 | 0.050 |
Why?
|
| Heart | 1 | 2023 | 219 | 0.050 |
Why?
|
| Lipids | 1 | 2023 | 195 | 0.050 |
Why?
|
| Nitrophenols | 1 | 2021 | 5 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 22 | 0.050 |
Why?
|
| Probiotics | 1 | 2021 | 16 | 0.050 |
Why?
|
| Lung | 1 | 2023 | 346 | 0.050 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2020 | 5 | 0.050 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Piperazines | 1 | 2021 | 45 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 68 | 0.040 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 5 | 0.040 |
Why?
|
| Platelet Count | 1 | 2021 | 112 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 82 | 0.040 |
Why?
|
| Adherens Junctions | 1 | 2019 | 8 | 0.040 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2020 | 44 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2019 | 15 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 913 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 1217 | 0.040 |
Why?
|
| Wound Healing | 1 | 2020 | 113 | 0.040 |
Why?
|
| Peptidoglycan | 1 | 2019 | 47 | 0.040 |
Why?
|
| Electroretinography | 1 | 2020 | 173 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2019 | 111 | 0.040 |
Why?
|
| Autonomic Nerve Block | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cathelicidins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 11 | 0.040 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2018 | 3 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 16 | 0.040 |
Why?
|
| Liver X Receptors | 1 | 2018 | 20 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2018 | 44 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 73 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 72 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 199 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2018 | 196 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2017 | 20 | 0.040 |
Why?
|
| Adult | 2 | 2020 | 7353 | 0.040 |
Why?
|
| Apoptosis | 1 | 2021 | 736 | 0.040 |
Why?
|
| Dinoprost | 2 | 2006 | 9 | 0.030 |
Why?
|
| PPAR delta | 1 | 2014 | 3 | 0.030 |
Why?
|
| Lipoprotein Lipase | 1 | 2014 | 10 | 0.030 |
Why?
|
| Adipose Tissue, Brown | 1 | 2014 | 13 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2014 | 41 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2014 | 31 | 0.030 |
Why?
|
| Foam Cells | 1 | 2013 | 8 | 0.030 |
Why?
|
| Animal Feed | 1 | 2013 | 20 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 65 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2013 | 36 | 0.030 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2012 | 5 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2012 | 18 | 0.030 |
Why?
|
| Thyroxine | 1 | 2012 | 11 | 0.030 |
Why?
|
| Spleen | 1 | 2013 | 109 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2008 | 8 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2008 | 11 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2008 | 12 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 151 | 0.020 |
Why?
|
| Cell Size | 1 | 2006 | 22 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2006 | 12 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2006 | 8 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2006 | 15 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2006 | 27 | 0.020 |
Why?
|
| Middle Aged | 1 | 2018 | 6791 | 0.020 |
Why?
|
| Superoxides | 1 | 2006 | 60 | 0.020 |
Why?
|
| Child | 1 | 2013 | 2144 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2006 | 12 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 587 | 0.020 |
Why?
|
| Biological Factors | 1 | 2006 | 11 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 65 | 0.020 |
Why?
|
| Testis | 1 | 2006 | 35 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 65 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2006 | 73 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2006 | 79 | 0.020 |
Why?
|
| Free Radicals | 1 | 2006 | 39 | 0.020 |
Why?
|
| Lipid Peroxidation | 1 | 2006 | 47 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 2949 | 0.020 |
Why?
|
| Arteries | 1 | 2006 | 64 | 0.020 |
Why?
|